Video
Maria Rescigno, professor at Humanitas University, discusses with MicrobioomePost what emerged at MicrobiotaMI congress 2023.
Industry, Video
Sponsored by
Marco Caspani, Executive Director of the Microbiome Division of Sacco System, explains how the company is directing his efforts and strong focus to the field of Biotherapeutics with the launch of…
Gabriel Leventhal, Chief Scientific Officer at Pharmabiome, spoke about NicheMap, a reference database that allows us to select the most appropriate strains to engineer targeted changes in the microbiome.
Colette Shortt, Regulatory Specialist and Visiting Professor University of Ulster, spoke about the regulatory framework for food supplements and Live Biotherapeutic products.
Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, spoke about how the research in gut-brain axes could pave the way to new microbiome based therapies in neurodegenerative diseases.
Tim Sharpington, Chief Executive Officer at Microbiotica, talked about how the microbiome field should navigate through a difficult financing horizon.
Clara Desvignes, Head of Microbiome at VCLS, spoke about the continuously evolving regulatory landscape on Fecal Microbiome Transplant.
Christopher Reyes, CEO, Co-Founder and Director at Bloom Science, spoke about the new class of microbe-based therapeutics for neurological disorders the company is working on.
Herve Affagard, Chief Executive Officer at MaaT Pharma, gives us an update on the clinical trials (Maat013 and Maat033) and describes the vision of the company for the future of the…
MicrobiomePost discussed with Claire Derlot, Head of Programs at Biose Industrie, the GMP challenges when you have to go from bacteria to a drug.
